Latest Articles
New Perspectives on the Use of Resveratrol in the Treatment of Metabolic and Estrogen-Dependent Conditions Through Hormonal Modulation and Anti-Inflammatory Effects.
Estrogen-dependent conditions, such as endometriosis, adenomyosis, lipedema, polycystic ovary syndrome, and breast cancer, are intimately involved with hormonal changes related to estrogen and their receptors. These conditions can be expressed …
Published: Aug. 27, 2025, midnight
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer - CancerNetwork
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer CancerNetwork
Published: Aug. 26, 2025, 10:07 p.m.
Genmab's Rina-S: A Game-Changer in Endometrial Cancer and a Catalyst for Shareholder Value - AInvest
Genmab's Rina-S: A Game-Changer in Endometrial Cancer and a Catalyst for Shareholder Value AInvest
Published: Aug. 26, 2025, 7:31 p.m.
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer - Targeted Oncology
FDA Breakthrough Therapy Granted for Novel ADC in Endometrial Cancer Targeted Oncology
Published: Aug. 26, 2025, 6:30 p.m.
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer - Oncology Nursing News
Rina-S Given Breakthrough Therapy Designation in Endometrial Cancer Oncology Nursing News
Published: Aug. 26, 2025, 6:04 p.m.
Genmab's Rina-S: A Breakthrough in Endometrial Cancer and a Catalyst for Shareholder Value - AInvest
Genmab's Rina-S: A Breakthrough in Endometrial Cancer and a Catalyst for Shareholder Value AInvest
Published: Aug. 26, 2025, 5:39 p.m.
Rina-S Earns Breakthrough Designation in Advanced Endometrial Cancer - Curetoday
Rina-S Earns Breakthrough Designation in Advanced Endometrial Cancer Curetoday
Published: Aug. 26, 2025, 4:06 p.m.
Olaparib Maintenance in Advanced Endometrial Cancer Trial - BIOENGINEER.ORG
Olaparib Maintenance in Advanced Endometrial Cancer Trial BIOENGINEER.ORG
Published: Aug. 26, 2025, 3:07 p.m.
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer - OncLive
Rina-S Wins FDA Breakthrough Therapy Designation for Advanced or Recurrent Endometrial Cancer OncLive
Published: Aug. 26, 2025, 3:01 p.m.
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) - Yahoo Finance
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) Yahoo Finance
Published: Aug. 26, 2025, noon
Link copied to clipboard!